17 completed, 3 terminated. 20 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 17, Terminated 3 |
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Synta Pharmaceuticals Corp.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of Ganetespib in Combination With Doxorubicin Ganetespib, Doxorubicin - Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Georgetown University | 11 | 2014-10-01 | 2018-04-23 |
| SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) ganetespib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma | Phase 1 / Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 20 | 2013-12-01 | 2019-05-15 |
| An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer ganetespib - Breast Cancer, HER-2 Positive Breast Cancer | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 51 | 2012-07-01 | 2015-11-05 |
| A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Ganetespib - Non Small Cell Lung Cancer | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 12 | 2012-04-01 | 2015-05-20 |
| STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma STA-9090 - Melanoma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 3 | 2011-09-01 | 2017-04-12 |
| Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Docetaxel, Combination of ganetespib and docetaxel - Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | Phase 2 / Phase 3 | Terminated | Synta Pharmaceuticals Corp. | 385 | 2011-05-01 | 2015-11-05 |
| Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer STA-9090 - Breast Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 22 | 2011-01-01 | 2015-11-20 |
| STA-9090(Ganetespib) in Metastatic Ocular Melanoma STA-9090 - Ocular Melanoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 17 | 2010-09-17 | 2018-10-18 |
| STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer STA-9090 - Esophagogastric Cancer | Phase 2 | Completed | Massachusetts General Hospital | 28 | 2010-08-01 | 2023-11-02 |
| Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer STA-9090 - Small Cell Lung Cancer | Phase 2 | Completed | David M. Jackman, MD | 25 | 2010-07-28 | 2019-04-16 |
| Clinical and Translational Study of STA-9090 STA-9090 - Colon Cancer, Rectal Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 20 | 2010-04-01 | 2015-11-20 |
| A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Ganetespib - Gastrointestinal Stromal Tumor | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 27 | 2010-01-01 | 2016-03-10 |
| A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) STA 9090 - Non Small Cell Lung Cancer | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 113 | 2009-11-01 | 2014-09-19 |
| A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes STA 5326 mesylate, Placebo - Active, Moderate to Severe Rheumatoid Arthritis | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 35 | 2005-12-01 | 2014-02-04 |
| Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease STA-5326 mesylate - Crohn's Disease | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 12 | 2005-11-01 | 2008-12-04 |
| Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease STA-5326 mesylate - Crohn's Disease | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 282 | 2005-08-01 | 2008-12-04 |
| A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas STA-4783 - Soft Tissue Sarcoma | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 80 | 2004-07-01 | 2006-06-20 |
| STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma STA-4783, Paclitaxel - Melanoma | Phase 1 / Phase 2 | Completed | Synta Pharmaceuticals Corp. | 103 | 2004-05-01 | 2014-03-06 |
| STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) Paclitaxel, Carboplatin, STA 4783 - Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Synta Pharmaceuticals Corp. | 86 | 2004-03-01 | 2008-12-04 |
| STA-5326 in Crohn's Disease Patients STA-5326 - Crohn's Disease | Phase 1 / Phase 2 | Completed | Synta Pharmaceuticals Corp. | 48 | 2004-02-01 | 2005-06-24 |
Carcinoma, Non-Small-Cell Lung (4) · Crohn Disease (3) · Breast Neoplasms (2) · Lung Neoplasms (2) · Melanoma (2) · Neoplasm Metastasis (2) · Sarcoma (2) · Small Cell Lung Carcinoma (2) · Colonic Neoplasms (1) · Gastrointestinal Stromal Tumors (1) · Motor Activity (1) · Neoplasms (1) · Neurofibrosarcoma (1) · Rectal Neoplasms (1) · Recurrence (1)
STA 9090 (12) · apilimod (4) · elesclomol (3) · Paclitaxel (2) · Carboplatin (1) · Docetaxel (1) · Doxorubicin (1) · Sirolimus (1)
United States (19) · Canada (4) · Belgium (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Bosnia and Herzegovina (1) · Brazil (1) · Croatia (1) · Czechia (1) · Germany (1) · Netherlands (1) · Peru (1) · Poland (1) · Romania (1)
AeRang Kim, MD, PhD (1) · Andrea Cercek, MD (1) · Brigitte Widemann, MD (1) · Bruce Sands, MD (1) · David Jackman, MD (1) · F. Stephen Hodi, M.D. (1) · F. Stephen Hodi, MD (1) · Giuseppe Giaccone, MD PhD (1) · Jeffrey W Clark, MD (1) · Peter Mannon, MD (1) · Shanu Modi, MD (1)